Investment Opportunity
£2.5M Asset-Backed Pharmaceutical Export Opportunity
A near-complete South African production facility designed for GACP and EU-GMP export into UK and European medical markets.
→ ~£3.5M already invested | Secured structure | Clear path to revenue
Investment Overview
Raise Amount
£2.5m
Asset Backing
Significant capital already deployed reduces development risk
Structure
Secured loan + 10% equity participation
Target Markets
UK, Germany, Israel, Portugal
Capital Invested
~£3.5M
Production Capacity
2–4 tonnes annually
Total Project Cost
~£5M
Pricing
GACP ~$2.50/g | EU-GMP ~$6/g
Investment Structure: Targeting a structured return through a secured loan component with additional equity upside.
Project Overview
→ A late-stage pharmaceutical cultivation facility with tangible asset backing.
→ The project is located on privately owned land near Rustenburg, South Africa. The head house is completed, grow room pads are in place, and the facility has been designed with EU-GMP export standards in mind.
→ The business is positioned as a regulated pharmaceutical supply-chain asset rather than a speculative cultivation start-up.
→ The facility is designed to reach first revenue shortly after completion and initial GACP approval.
Market Opportunity
→ European prescription medical markets continue to require consistent, compliant supply.
→ The opportunity is to complete a lower-cost South African production base capable of serving international medical markets under GACP standards and, in due course, EU-GMP certification.
→ This positioning enables access to higher-value export markets with limited compliant supply.
Investment Rationale
Significant capital already deployed reduces development risk
Physical asset backing provides downside protection
Lower-cost South African production with access to higher-value EU markets
Clear value uplift through EU-GMP certification
Experienced local operators with regulatory expertise
Positioned within a growing global pharmaceutical supply chain
Key Highlights
Substantial founder capital already invested
Late-stage physical infrastructure, not concept stage
Asset-backed through land and facility
Experienced South African operating team
Responsible pharmacist supporting regulatory pathway
Defined route to revenue and export markets
Scalable production model
Use Of Funds
→ The £2.5M raise is allocated to defined completion milestones:
1. Completion of grow rooms
2. Final infrastructure and utilities
3. Licensing and compliance pathway
4. Working capital to first production
5. Progression to GACP and EU-GMP certification
Next Steps
We are currently engaging with a limited number of investors and capital partners to complete this raise.
→ Full investment materials, including financial model and technical details, are available upon request.
Investor Enquiries
For further information please request the full investment pack below.
Operated by Happy Pharma Pty Ltd
This opportunity is intended for sophisticated, high-net-worth and professional investors only. Information is provided for discussion purposes and does not constitute financial advice or a public investment offer.
© 2026 Happy Pharma Pty Ltd. All rights reserved.